Receptor Integral To Or Derived From A Lymphocytic Or Lymphocytic-like Cell (e.g., Nk Cell, Etc.) Patents (Class 424/144.1)
-
Patent number: 8580255Abstract: The present invention provides compositions and methods for the treatment of autoimmune diseases, in particular rheumatoid arthritis. Compounds which function as antagonists of Toll-like Receptor 2 are shown to suppress the immune response which result in the onset and progression of autoimmune disease. In particular monoclonal antibodies which have a binding specificity to Toll-like receptor 2 are disclosed for use in methods for the treatment and/or prophylaxis of autoimmune disease.Type: GrantFiled: June 27, 2008Date of Patent: November 12, 2013Assignee: OPSONA Therapeutics LtdInventors: Mark Heffernan, Luke O'Neill, Peter McGuirk, Brian Keogh, Christopher Locher
-
Patent number: 8575317Abstract: The present inventors successfully obtained anti-NR10 antibodies having an effective neutralizing activity against NR10. The anti-NR10 antibodies provided by the present invention are useful as, for example, pharmaceuticals for treating or preventing inflammatory diseases.Type: GrantFiled: December 4, 2009Date of Patent: November 5, 2013Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Taichi Kuramochi, Keiko Kasutani, Souhei Ohyama, Hiroyuki Tsunoda, Tomoyuki Igawa, Tatsuhiko Tachibana, Hirotake Shiraiwa, Keiko Esaki
-
Patent number: 8568721Abstract: The present invention provides methods of preventing or treating rheumatoid arthritis using a fully human antibody or antigen-binding fragment thereof that specifically binds human interleukin-6 receptor (hIL-6R). The methods of the present invention may include administration of a second therapeutic agent, such as one or more of a non-steroidal anti-inflammatory drug (NSAID), a glucocorticoid, a disease-modifying anti-rheumatic drug (DMARD), or a TNF-alpha antagonist, T-cell blocker, anti-CD20 antibody, an IL-1, JAK or IL-17 antagonist, or any combination thereof.Type: GrantFiled: May 3, 2012Date of Patent: October 29, 2013Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Allen Radin, Sean Stevens, Tammy T. Huang, Joel H. Martin, Jeanette L. Fairhurst, Ashique Rafique, Eric Smith, Kevin J. Pobursky, Nicholas J. Papadopoulos, James P. Fandl, Gang Chen, Margaret Karow
-
Patent number: 8568722Abstract: High affinity antibody antagonists of human interleukin-13 receptor alpha 1 are disclosed. The antibody molecules are effective in the inhibition of IL-13R?1-mediated activities and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with hIL-13R?1 activity. The present invention also discloses nucleic acid encoding said antibody molecules, vectors, host cells, and compositions comprising the antibody molecules. Methods of using the antibody molecules for inhibiting or antagonizing IL-13R?1-mediated activities are also disclosed.Type: GrantFiled: May 6, 2010Date of Patent: October 29, 2013Assignee: CSL LimitedInventors: Andrew Donald Nash, Manuel Baca, Louis Jerry Fabri, Dennis Zaller, William R. Strohl, Zhiqiang An
-
Patent number: 8568725Abstract: A mutant of a potentially therapeutic anti-CD40 antibody is provided which mutant has reduced ADCC and CDC activities designed to be optimized as a pharmaceutical agent. A mutant of an agonistic anti-CD40 antibody, comprising mutation and/or substitution of at least one amino acid in the constant region to reduce the ADCC and/or CDC activities therein, and a mutant of an antagonistic anti-CD40 antibody, comprising at least one mutation or substitution in the constant region to reduce the ADCC and/or CDC activities therein, both mutants having at least a hinge region derived from a human IgG2.Type: GrantFiled: December 24, 2004Date of Patent: October 29, 2013Assignee: Kyowa Hakko Kirin Co., Ltd.Inventors: Nobuaki Takahashi, Toru Miura, Yoshinori Kitagawa, Aki Hirano
-
Publication number: 20130280265Abstract: The present disclosure provides combinations of immunotherapeutics and methods for treating medical conditions that are characterized by the lack of an effective immune response, for example as would result following a down-regulation of MHC class I, such as in cancer. The immunotherapeutic compositions of the invention, which can be used to treat the medical conditions, include one or more immunostimulatory antibodies or molecules having specificity for CTLA-4, PD-1, PD-L1, PD-L2, CD40, OX40, CD137, GITR, ILT2, or ILT3, or ligands for these molecules (e.g., an isolated fully-human monoclonal antibody) in association with one or more alloantigens, such as, vector(s) capable of expressing protein(s) or peptide(s) that stimulate T-cell immunity against tissues or cells, formulated in a pharmaceutically acceptable carrier. The proteins or peptides may comprise class I major histocompatibility complex (MHC) antigens, ?2-microglobulins, or cytokines. The MHC antigen may be foreign to the subject.Type: ApplicationFiled: March 14, 2013Publication date: October 24, 2013Inventor: Vical Incorporated
-
Patent number: 8562992Abstract: The invention provides humanized and chimeric anti-CD20 antibodies for treatment of CD20 positive malignancies and autoimmune diseases.Type: GrantFiled: October 22, 2008Date of Patent: October 22, 2013Assignee: Genentech, Inc.Inventors: Camellia W. Adams, Andrew C. Chan, Craig W. Crowley, Henry B. Lowman, Gerald R. Nakamura, Leonard G. Presta
-
Patent number: 8557245Abstract: The invention features methods and compositions for preventing or treating bone cancer pain including cancer pain associated with bone metastasis by administering an antagonist of nerve growth factor (NGF). The NGF antagonist may be an anti-NGF (such as anti-hNGF) antibody that is capable of binding hNGF.Type: GrantFiled: June 13, 2012Date of Patent: October 15, 2013Assignees: Rinat Neuroscience Corp., Regents of The University of MinnesotaInventors: David L. Shelton, Patrick William Mantyh
-
Patent number: 8557244Abstract: This invention concerns methods for the treatment of intermediate and high-grade non-Hodgkins lymphomas, comprising the administration of anti-CD20 monoclonal antibodies and fragments thereof. Particular embodiments include the administration of chimeric anti-CD20 antibody, either alone or in combination with radiolabeled antibodies or chemotherapy. The invention is particularly useful for lymphomas characterized by a high number of circulating B cells, possibly bone marrow involvement, bulky disease, or the involvement of extralymphatic organs or sites.Type: GrantFiled: July 28, 2000Date of Patent: October 15, 2013Assignee: Biogen Idec Inc.Inventors: Christine White, Antonio Grillo-Lopez
-
Patent number: 8551478Abstract: The present invention is related to antibodies directed to the antigen CD3 and uses of such antibodies. In particular, the present invention provides fully human monoclonal antibodies directed to CD3. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.Type: GrantFiled: March 30, 2010Date of Patent: October 8, 2013Assignee: NovImmune S.A.Inventors: Bernard Mach, Yann Dean, Marie Kosco-Vilbois, Greg Elson, Nicolas Fischer, Olivier Leger
-
Patent number: 8551485Abstract: The present invention describes humanized antibodies that target CD40, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an Fc?R or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention.Type: GrantFiled: January 21, 2009Date of Patent: October 8, 2013Assignee: Xencor, Inc.Inventors: Matthew J. Bernett, Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Erik WeiKing Pong, Eugene Alexander Zhukovsky
-
Patent number: 8551483Abstract: Described are methods of treating viral disease using compounds that block inhibitory NK cell receptors, thereby reducing their inhibition of NK cell cytotoxicity in killing infected target cells. In one embodiment, the compound is an antibody binding, for example, one or more of the human KIR2DL1, KIR2DL2, and KIR2DL3 receptors. In another embodiment, the method further comprises administering a therapeutic antibody or fusion protein which binds an antigen expressed on cells infected with the virus.Type: GrantFiled: January 6, 2006Date of Patent: October 8, 2013Assignees: Innate Pharma S.A.S., Novo Nordisk A/SInventors: Peter Andreas Nicolai Reumert Wagtmann, Francois Romagne, Joakim Glamann
-
Patent number: 8545843Abstract: The present invention concerns treatment of autoimmune diseases with antagonists which bind to B cell surface markers, such as CD19 or CD20.Type: GrantFiled: September 20, 2010Date of Patent: October 1, 2013Assignees: Genentech, Inc., Biogen Idec Inc.Inventors: John G. Curd, Antonio J. Grillo-Lopez
-
Publication number: 20130251675Abstract: The invention is directed to novel methods for modulating inflammatory and/or immune responses. Such methods utilize compositions comprising extraembryonic cells (herein referred to as EE cells) including but not limited to extraembryonic HLA-G positive cells (herein referred to as EHP cells) and amnion-derived multipotent progenitor cells (herein referred to as AMP cells); compositions comprising expanded EE cell populations, and/or cell lysates and/or conditioned media derived therefrom, alone or in combination with each other and/or in combination with various extracellular matrices and/or devices and/or other suitable active agents.Type: ApplicationFiled: February 23, 2013Publication date: September 26, 2013Applicant: STEMNION, INC.Inventors: Richard A Banas, Catherine J. Trumpower
-
Patent number: 8535672Abstract: Disclosed are methods and compositions for the inhibition of modulation of T cell costimulatory pathway by a pathogenic agent, particularly, the inhibition of activation of a T cell costimulatory pathway, preferably, the CD28/B7 pathway, by a pyrogenic exotoxin. The method of the invention is based on the inhibition of the direct interaction of a superantigen with a specific site within the dimer interface of a CD28 family member, using immunomodulatory peptides. Further disclosed are specific antagonist immunomodulatory peptides comprising an amino acid sequence derived from a dimer interface of a T cell co-stimulatory pathway member, or peptides which comprise an amino acid sequence which specifically binds to an amino acid sequence within the dimer interface of a T cell co-stimulatory pathway member. Compositions comprising said peptides and methods for the treatment of immune-related disorders are also disclosed.Type: GrantFiled: October 4, 2004Date of Patent: September 17, 2013Assignee: Yissum Research Development of the Hebrew University of JerusalemInventors: Raymond Kaempfer, Gila Arad
-
Patent number: 8530627Abstract: The present invention relates to antibodies or fragments thereof that specifically bind Fc?RIIB, particularly human Fc?RIIB, with greater affinity than said antibodies or fragments thereof bind Fc?RIIA, particularly human Fc?RIIA. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention.Type: GrantFiled: July 3, 2008Date of Patent: September 10, 2013Assignee: MacroGenics, Inc.Inventors: Scott Koenig, Maria Concetta Veri
-
Patent number: 8529902Abstract: Isolated human monoclonal antibodies which bind to and inhibit human CD20, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.Type: GrantFiled: October 17, 2003Date of Patent: September 10, 2013Assignee: Genmab A/SInventors: Jessica Teeling, Sigrid Ruuls, Martin Glennie, Jan G. J. van de Winkel, Paul Parren, Jørgen Petersen, Ole Baadsgaard, Haichun Huang
-
Publication number: 20130230534Abstract: The present invention provides isolated human monoclonal antibodies that bind to IFNAR-1 and that are capable of inhibiting the biological activity of Type I interferons. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting Type I interferon-mediated disorders using the antibodies of the invention, including methods for treating autoimmune disorders, transplant rejection or Graft Versus Host Disease using the antibodies of the invention.Type: ApplicationFiled: May 9, 2013Publication date: September 5, 2013Applicant: MEDAREX, INC.Inventors: JOSEPHINE M. CARDARELLI, ALISON WITTE, MOHAN SRINIVASAN
-
Patent number: 8524236Abstract: The invention relates to antibody polypeptides that monovalently bind CD40L. Antibody polypeptides that are monovalent for binding of CD40L can inhibit CD40L activity while avoiding potential undesirable effects that can occur with antibodies capable of divalent or multivalent binding of CD40L. In one aspect, a monovalent anti-CD40L antibody polypeptide consists of or comprises a single immunoglobulin variable domain that specifically binds and antagonizes the activity of CD40L, preferably without substantially agonizing CD40 and/or CD40L activity. In another aspect, the monovalent anti-CD40L antibody polypeptide is a human antibody polypeptide. The invention further encompasses methods of antagonizing CD40/CD40L interactions in an individual and methods of treating diseases or disorders involving CD40/CD40L interactions, the methods involving administering a monovalent anti-CD40L antibody polypeptide to the individual.Type: GrantFiled: September 16, 2005Date of Patent: September 3, 2013Assignee: Domantis LimitedInventors: Steven Grant, Haiqun Liu, Kevin Moulder
-
Patent number: 8524234Abstract: The present invention provides compositions, methods, and assays for treating an inflammatory and/or autoimmune disease, and/or transplanted tissue rejection using anti-?? TCR antibodies and antibody fragments. Anti-?? TCR antibodies are antibodies which bind to a ?? TCR. Anti-?? TCR antibodies produced by the hybridoma TOL101 MCB are also provided. Methods for treatment of an inflammatory disease, an autoimmune disease and for tissue transplant rejection using therapeutic dosing regimen of anti-?? TCR antibodies and antibody fragments and for upregulating the numbers of Treg T-cells are also provided.Type: GrantFiled: November 5, 2012Date of Patent: September 3, 2013Assignee: Tolera Therapeutics, IncInventors: Daniel R. Getts, James J. Herrmann, John J. Puisis, Frank J. Fokta
-
Patent number: 8524672Abstract: Disclosed are nucleic acids encoding BAFF-R polypeptides, as well as antibodies to BAFF-R polypeptides and pharmaceutical compositions including the same. Methods of treating tumorigenic and autoimmune conditions using the nucleic acids, polypeptides, antibodies and pharmaceutical compositions of this invention are also provided.Type: GrantFiled: August 19, 2011Date of Patent: September 3, 2013Assignee: Biogen Idec MA Inc.Inventors: Christine M. Ambrose, Jeffrey S. Thompson
-
Patent number: 8524233Abstract: The present invention relates to a humanized IgG1 isotype anti-CD6 antibody (T1h) that binds to the Scavenger receptor cysteine-rich (SRCR) domain 1 (D1) of CD6 present on the surface of thymic epithelial cells, monocytes, activated T cells and a variety of other cells types.Type: GrantFiled: September 4, 2008Date of Patent: September 3, 2013Assignee: Biocon Limited & Centro de Immunologia MolecularInventors: Ramakrishnan Melarkode, Pradip Nair, Sundaraj David Rajkumar, Kedarnath Nanjund Sastry, Monalisa Chatterji, Laxmi Adhikary, Hema Balasubramanian, Jose Enrique Montero Casimiro, Josefa Lombardero Valladares, Rolando Perez Rodriguez
-
Patent number: 8524867Abstract: Antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an FcyR or alters effector function as compared to the parent antibody, and methods of using the antibodies.Type: GrantFiled: August 14, 2007Date of Patent: September 3, 2013Assignee: Xencor, Inc.Inventors: Matthew J. Bernett, Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Erik WeiKing Pong, John O. Richards, Eugene Alexander Zhukovsky
-
Patent number: 8518407Abstract: Antibodies that interact with interleukin-1 receptor type 1 (IL-1R1) are described. Methods of treating IL-1 mediated diseases by administering a pharmaceutically effective amount of antibodies to IL-1R1 are described. Methods of detecting the amount of IL-1R1 in a sample using antibodies to IL-1R1 are described.Type: GrantFiled: April 18, 2012Date of Patent: August 27, 2013Assignees: Amgen Inc., Medarex, Inc.Inventors: Brian Varnum, Chris Vezina, Alison Witte, Xueming Qian, Francis Hall Martin, Haichun Huang, Gary Elliott
-
Patent number: 8518403Abstract: A composite polypeptide, said composite polypeptide comprising a desired polypeptide and an expression enhancing domain (“EED”), said EED comprising first and second cysteine amino acid residues Cys1 and Cys2, respectively, Cys1 being located closer to the N-terminus of the composite polypeptide molecule than Cys2, wherein Cys1 and Cys2 are separated by a polypeptide linker, said linker—being free of cysteine and proline;—defining a length sufficient to allow Cys1 and Cys2 to engage in an intramolecular disulfide bond with one another; and—having a flexible polypeptide conformation essentially free of secondary polypeptide structure in aqueous solution, wherein at least one of Cys1 and Cys2 is derivatized with a derivatization moiety.Type: GrantFiled: July 15, 2005Date of Patent: August 27, 2013Assignee: Amgen Research (Munich) GmbHInventors: Patrick Hoffmann, Silke Mittelstrass, Jens Hennecke, Tobias Raum
-
Publication number: 20130216498Abstract: New imidazopyridine derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).Type: ApplicationFiled: December 23, 2010Publication date: August 22, 2013Inventors: Paul Robert Eastwood, Jacob Gonzales Rodriguez, Jordi Bach Taña, Lluis Miquel Pages Santacana, Joan Taltavull Moll, Juan Francisco Caturla Javaloyes, Victor Giulio Matassa
-
Publication number: 20130216476Abstract: The use of an anti-CD71 monoclonal antibody or a fragment of an abovementioned antibody capable of binding to the CD71 antigen for the preparation of a drug intended for the prevention or treatment of myelomas.Type: ApplicationFiled: May 3, 2011Publication date: August 22, 2013Applicant: LFB BIOTECHNOLOGIESInventor: Laurence Boumsell
-
Patent number: 8512704Abstract: The present invention relates to an antibody directed to a beta cell marker protein, in particular to an antibody directed to the protein TMEM27.Type: GrantFiled: July 30, 2010Date of Patent: August 20, 2013Assignee: Genentech, Inc.Inventors: Kerstin Jahn-Hofmann, Sannah Zoffmann Jensen, Hugues Matile, Cristiano Migliorini, Haiyan Wang
-
Patent number: 8506960Abstract: Binding members for alpha chain of receptor for granulocyte macrophage colony stimulating factor (GM-CSFR?), especially antibody molecules. Use of the binding members in treating inflammatory and autoimmune diseases, e.g. rheumatoid arthritis, asthma, allergic response, multiple sclerosis, myeloid leukaemia and atherosclerosis.Type: GrantFiled: March 27, 2007Date of Patent: August 13, 2013Assignees: MedImmune Limited, Zenyth Operations Pty. Ltd.Inventors: Emma Suzanne Cohen, Ralph Raymond Minter, Paula Rosamund Harrison, Matthew Alexander Sleeman, Andrew Donald Nash, Louis Jerry Fabri
-
Patent number: 8501943Abstract: The present disclosure is directed to the sodium salt of 5-cyclopropyl-2-{[2-(2,6-difluorophenyl)pyrimidin-5-yl]amino}benzoic acid, pharmaceutically acceptable solvates thereof, pharmaceutical combinations thereof, and methods of treatment.Type: GrantFiled: March 11, 2010Date of Patent: August 6, 2013Assignee: Almirall, S.A.Inventors: Nuria Garcia Gonzalez, Francesc Carrera Carrera, Monserrat Julia Jane, Laurent Debethune, Xavier Serra Masia
-
Patent number: 8491898Abstract: The invention pertains to anti-CD30 antibodies that lack fucosyl residues. The antibodies of the invention exhibit increased antibody-dependent cellular cytotoxicity (ADCC) activity, including the ability to lyse CD30-expressing cell lines that are not lysed by the fucosylated form of the antibodies. The invention also provides host cells that express the anti-CD30 antibodies that lack fucosyl residues, wherein the host cells are deficient for a fucosyl transferase. Methods of using the antibodies to inhibit the growth of CD30+ cells, such as tumor cells, are also provided.Type: GrantFiled: May 2, 2012Date of Patent: July 23, 2013Assignee: Medarex, L.L.C.Inventors: Josephine M. Cardarelli, Amelia Nancy Black
-
Patent number: 8486395Abstract: The present invention provides humanized, chimeric and human anti-CD19 antibodies, anti-CD19 antibody fusion proteins, and fragments thereof that bind to a human B cell marker. Such antibodies, fusion proteins and fragments thereof are useful for the treatment and diagnosis of various B-cell disorders, including B-cell malignancies and autoimmune diseases. In more particular embodiments, the humanized anti-CD19 antibodies may comprise one or more framework region amino acid substitutions designed to improve protein stability, antibody binding and/or expression levels. In a particularly preferred embodiment, the substitutions comprise a Ser91Phe substitution in the hA19 VH sequence.Type: GrantFiled: November 19, 2012Date of Patent: July 16, 2013Assignee: Immunomedics, Inc.Inventors: Hans J. Hansen, Zhengxing Qu, David M. Goldenberg
-
Patent number: 8486394Abstract: The present invention provides novel antibodies and functional fragments thereof specific for CD38, and methods of using the same for the treatment of diseases associated with CD38 expression, including hematological malignancies such as multiple myeloma.Type: GrantFiled: November 8, 2011Date of Patent: July 16, 2013Assignee: Morphosys AGInventors: Michael Tesar, Ute Jäger
-
Patent number: 8481683Abstract: The present disclosure provides isolated monoclonal antibodies that specifically bind to CD22 with high affinity, particularly human monoclonal antibodies. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting CD22, as well as methods for treating various cancers and inflammatory and autoimmune disorders using an anti-CD22 antibody of this disclosure.Type: GrantFiled: November 30, 2007Date of Patent: July 9, 2013Assignee: Medarex, Inc.Inventors: David John King, Alison Witte, Heidi N. LeBlanc, Richard Theolis, Asna Masood, Mark Yamanaka, Kyra D. Zens, Sarah R. Reed, Tim Sproul, Chetana Rao-Naik, David Passmore, Dawn M. Tanamachi, Kristopher Toy
-
Patent number: 8481022Abstract: Methods and compositions for treating an autoimmune disease, such as new onset type 1 diabetes (T1D) in a subject using autologous or allogeneic mesenchymal stem cells administered to the subject prior to autoimmune-induced complete depletion of insulin-producing pancreatic beta cells, e.g., within six months of new onset type 1 diabetes (T1D) diagnosis or prior to the onset of disease in a subject determined to be at high risk for T1D.Type: GrantFiled: July 28, 2011Date of Patent: July 9, 2013Assignee: Genzyme CorporationInventors: Tracey Lodie, Michele Youd, Ross Tubo, Scott Eisenbeis
-
Publication number: 20130156768Abstract: Compositions and methods are disclosed which are useful of the treatment and prevention of proliferative disorders.Type: ApplicationFiled: August 25, 2011Publication date: June 20, 2013Applicant: Bristol-Myers Squibb CompanyInventors: Maria Jure-Kunkel, Jon Marc Wigginton, Ashok Kumar Gupta
-
Patent number: 8465741Abstract: The invention provides antibodies, including chimeric human antibodies, recombinant antibodies, synthetic antibodies, and the nucleic acids encoding them, and methods for making and using these immunoglobulins. The invention provides recombinant and synthetic polypeptide and nucleic acid embodiments of these polypeptides and/or antibodies. The invention also provides polypeptides comprising, or consisting of, consensus human framework regions, or “Independently Consensused Frameworks (ICFs)”, nucleic acids encoding them, and libraries and kits comprising these ICFs and/or antibodies of the invention, individually and in combinatorial libraries and combinations.Type: GrantFiled: September 14, 2007Date of Patent: June 18, 2013Assignee: MMRGlobal, Inc.Inventors: Gerhard Frey, Bruce E. Kimmel, Abraham Anderson
-
Patent number: 8465739Abstract: This invention is directed to a stable liquid pharmaceutical formulation comprising a high concentration, e.g. 50 mg/ml or more, of antibody in about 20-60 mM succinate buffer or 30-70 mM histidine buffer, having pH from about pH 5.5 to about pH 6.5, about 0.01-0.1% polysorbate, and a tonicity modifier that contributes to the isotonicity of the formulation. This liquid formulation is stable at refrigerated temperature (2-8° C.) for at least 1 year, and preferably 2 years. This liquid formulation is suitable for subcutaneous injection. The preferred antibodies include Daclizumab, a humanized anti-IL-2 receptor monoclonal antibody; HAIL-12, a humanized anti-IL-12 monoclonal antibody; HuEP5C7, a humanized anti-L selectin monoclonal antibody; and Flintozumab, a humanized anti-gamma interferon monoclonal antibody.Type: GrantFiled: September 6, 2011Date of Patent: June 18, 2013Assignee: Abbvie Biotherapeutics Inc.Inventors: Elizabet A. Kaisheva, Supriya Gupta, Shanti G. Duvur, Malathy Subramanian
-
Patent number: 8461304Abstract: The present invention provides antibodies which bind to an epitope in the extracellular domain of human CC chemokine receptor 4 (CCR4) and which are capable of inhibiting the binding of macrophage-derived chemokine (MDC) and/or thymus and activation regulated chemokine (TARC) to CCR4. Also provided are inter alia immunoconjugates and compositions comprising such antibodies and methods and uses involving such antibodies, particularly in the medical and diagnostic fields.Type: GrantFiled: June 9, 2010Date of Patent: June 11, 2013Assignee: Affitech Research ASInventors: Lavinia Diana Cicortas Gunnarsson, Didrik Paus
-
Publication number: 20130142807Abstract: The invention encompasses compounds having formula I-V and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, may be therapeutically useful.Type: ApplicationFiled: January 25, 2013Publication date: June 6, 2013Applicant: Rigel Pharmaceuticals, Inc.Inventor: Rigel Pharmaceuticals, Inc.
-
Publication number: 20130136749Abstract: The present invention provides novel human sequence antibodies against human CTLA-4 and methods of treating human diseases, infections and other conditions using these antibodies.Type: ApplicationFiled: November 1, 2012Publication date: May 30, 2013Applicant: Medarex, Inc.Inventor: Medarex, Inc.
-
Patent number: 8445645Abstract: The present invention relates to molecules, particularly polypeptides, more particularly immunoglobulins (e.g., antibodies), comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, which variant Fc region binds Fc?RIIIA and/or Fc?RIIA with a greater affinity, relative to a comparable molecule comprising the wild-type Fc region. The molecules of the invention are particularly useful in preventing, treating, or ameliorating one or more symptoms associated with a disease, disorder, or infection. The molecules of the invention are particularly useful for the treatment or prevention of a disease or disorder where an enhanced efficacy of effector cell function (e.g., ADCC) mediated by Fc?R is desired, e.g., cancer, infectious disease, and in enhancing the therapeutic efficacy of therapeutic antibodies the effect of which is mediated by ADCC.Type: GrantFiled: June 10, 2011Date of Patent: May 21, 2013Assignee: MacroGenics, Inc.Inventors: Jeffrey Stavenhagen, Sujata Vijh, Christopher Rankin, Sergey Gorlatov, Ling Huang
-
Publication number: 20130122015Abstract: The present invention provides compositions, methods, and assays for treating an inflammatory and/or autoimmune disease, and/or transplanted tissue rejection using anti-?? TCR antibodies and antibody fragments. Anti-?? TCR antibodies are antibodies which bind to a ?? TCR. Anti-?? TCR antibodies produced by the hybridoma TOL101 MCB are also provided.Type: ApplicationFiled: November 5, 2012Publication date: May 16, 2013Applicant: Tolera Therapeutics, Inc.Inventor: Tolera Therapeutics, Inc.
-
Patent number: 8440195Abstract: A method of treating or reducing at least one inflammatory condition or the susceptibility to at least one inflammatory condition is provided involving administering at least one CD69 antagonist to a subject, wherein the subject has been diagnosed with at least one inflammatory condition, or a susceptibility to the same. CD69 antagonists can include one or more of an anti-CD69 antibody, an anti-CD69 aptamer, a CD69 mRNA antagonist, and a small molecule pharmaceutical.Type: GrantFiled: November 12, 2010Date of Patent: May 14, 2013Assignees: National University Corporation Chiba University, National University Corporation Yamaguchi UniversityInventors: Toshinori Nakayama, Akihiro Hasegawa, Mutsunori Shirai
-
Patent number: 8435521Abstract: The present invention is related to the branch of immunology and particularly with the generation of pharmaceutical compositions comprising a humanized monoclonal antibody recognizing the leukocyte differentiation antigen CD6. Accordingly with that statement, the purpose of this invention is to provide pharmaceutical compositions comprising a humanized anti-CD6 monoclonal antibody for the diagnosis and treatment of Lymphoproliferative Syndromes and particularly the B-Cell Chronic Lymphocytic Leukemia. The essence of the invention consist in the application of a humanized Monoclonal Antibody that recognizes the CD6 antigen, the generation of pharmaceutical compositions comprising that antibody being able to induce apoptosis of malignant cells from B-Cell Chronic Lymphocytic Leukemia patients, reaching a clinical and a histological antitumor efficacy. The field of application of the present invention extends to the Oncology.Type: GrantFiled: December 24, 2007Date of Patent: May 7, 2013Assignee: Centro de Immunolgia MolecularInventors: Jose Enrique Montero Casimiro, Ruby Alonso Ramirez, Rolando Perez Rodriguez
-
Publication number: 20130101597Abstract: The instant invention is based, at least in part, on the discovery that CXCR6 plays a critical role in antigen-specific effector function of NK cells. Accordingly, the invention provides, among other things, methods for modulation of antigen-specific NK cell effector function, methods for identifying modulators of antigen-specific NK cell effector function.Type: ApplicationFiled: December 1, 2010Publication date: April 25, 2013Applicant: PRESIDENT AND FELLOWS OF HARVARD COLLEGEInventors: Ulrich Von Andrian, Silke Paust
-
Patent number: 8425912Abstract: The invention relates to therapeutic conjugates with improved ability to target various cancer cells containing a targeting moiety and a therapeutic moiety. The targeting and therapeutic moieties are linked via an acid cleavable linkage that increases therapeutic efficacy of the immunoconjugate.Type: GrantFiled: August 15, 2012Date of Patent: April 23, 2013Assignee: Immunomedics, Inc.Inventor: Serengulam V. Govindan
-
Patent number: 8420092Abstract: The invention relates to use of the natural cytotoxicity receptor NKp46 for preventing and treating diabetes, including type I diabetes (TID) and type 2 diabetes. In particular, the invention provides compositions comprising a fragment of the extracellular region of NKp46 for preventing the onset and progression of diabetes.Type: GrantFiled: March 18, 2010Date of Patent: April 16, 2013Assignees: Ben-Gurion University of the Negev Research and Development Authority, Hadasit Medical Research Services and Development Ltd.Inventors: Ofer Mandelboim, Angel Porgador, Yaakov Naparstek, Chamutal Gur
-
Patent number: 8420784Abstract: The invention relates to IL-1O Receptor alpha (IL-1OR?) antibodies and subsequences thereof, human and humanized IL-10 Receptor alpha (IL-IOR?) antibodies and subsequences thereof, isolated and purified IL-10 Receptor alpha (IL-1OR?) antibodies and subsequences thereof, compositions including IL-10 Receptor alpha (IL-1OR?) antibodies and subsequences thereof, and methods that employ IL-10 Receptor alpha (IL-1OR?) antibodies and subsequences thereof. The invention includes among other things, methods of treating a pathogen infection, pathogen reactivation, and methods of vaccinating or immunizing against a pathogen infection, which include, for example, administering an IL-10 Receptor alpha (IL-1OR?) antibody or subsequence, to treat a pathogen infection, pathogen reactivation or for vaccination or immunization.Type: GrantFiled: May 27, 2009Date of Patent: April 16, 2013Assignee: Kyowa Hakko Kirin Co., Ltd.Inventors: Shinichiro Kato, Rachel Soloff Nugent, Tomoyuki Tahara, Paul Rogers, Aihua Song
-
Publication number: 20130089555Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.Type: ApplicationFiled: November 20, 2012Publication date: April 11, 2013Applicant: GENENTECH, INC.Inventor: Genentech, Inc.